Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2017.0262
NEWS & VIEWS
|
RNA-sequencing identifies a new molecular classification of pancreatic cancer: Implications and challenges.
|
Dimitrios K. Christodoulou, MD, PhD.
|
Affiliation: Dimitrios K. Christodoulou, (DKC), Professor of Gastrentorolgy, Department of Gastroenterology, Ioannina University Hospital, Ioannina, TK 45110, Greece.
E-mail: dchristodoulou@gmail.com |
Abstract
Prognosis of pancreatic ductal adenocarcinoma (PDA) remains grim. Advances and standardization of complete tumor resection (R0) and adjuvant chemotherapy have led to a 30-50% 5-year survival for patients with resectable, early-stage disease (T1N0). However, survival rates for more advanced stages are poor. The advent of next-generation sequencing (NGS) technologies a decade ago has revolutionized biomedical research. More recently, efforts are focused on how to translate the tremendous potential of NGS on the analysis of clinical cancer genome on patient-derived samples into clinical care.
(Citation: Gastric & Breast Cancer 2017; 12(2): 79-84)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 31 August 2017 |
|
